Previous 10 | Next 10 |
Delcath Systems Closes Private Placement of $6.2 Million PR Newswire NEW YORK , Dec. 13, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today a...
Delcath Systems Announces Private Placement of $6.2 Million PR Newswire NEW YORK , Dec. 8, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
Results of a Single Center Study on Delcath's CHEMOSAT® Hepatic Delivery System In the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis Results of a Single Center Study on Delcath's CHEMOSAT® Hepatic Delivery System In the Treatme...
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEW YORK , Nov. 9, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), announces that the Company granted equity awards, previously approved by the Com...
Start Time: 08:30 End Time: 09:00 Delcath Systems, Inc. (DCTH) Q3 2022 Earnings Conference Call November 08, 2022, 08:30 AM ET Company Participants Gerard Michel - CEO Anthony Dias - VP of Finance Johnny John - VP, Clinical Development & Medical Affai...
Delcath Systems ( NASDAQ: DCTH ), a medical device maker focused on liver cancers, dropped ~6% in the morning hours Tuesday, even after the company's Q3 2022 revenue exceeded the consensus. Delcath ( DCTH ) reported $906K in revenue for the quarter, indicating ~74% Y...
Delcath Systems press release ( NASDAQ: DCTH ): GAAP EPS of -$0.92. Revenue of $0.9M (+80.0% Y/Y) beats by $0.09M . Shares +24% PM. For further details see: Delcath Systems GAAP EPS of -$0.92, revenue of $0.9M beats by $0.09M
Delcath Systems Reports Third Quarter 2022 Results and Provides Business Update PR Newswire NEW YORK , Nov. 8, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic...
Delcath Systems ( NASDAQ: DCTH ) is scheduled to announce Q3 earnings results on Tuesday, November 8th, before market open. The consensus EPS Estimate is -$1.04 (-10.6% Y/Y) and the consensus Revenue Estimate is $0.81M (+55.8% Y/Y). Over the last 1 year, DCTH has bea...
Delcath Systems to Host Third Quarter 2022 Results PR Newswire NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, annou...
News, Short Squeeze, Breakout and More Instantly...
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 5, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024...
2024-07-16 23:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 07:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...